Brief: Lineage Enters Into Option And License Agreement With Eterna Therapeutics
22/02/2023 17:31
Feb 22 (Reuters) - Lineage Cell Therapeutics Inc
LCTX.A :
* LINEAGE ENTERS INTO OPTION AND LICENSE AGREEMENT WITH
ETERNA
THERAPEUTICS TO DEVELOP HYPOIMMUNE PLURIPOTENT CELL LINES FOR
MULTIPLE NEUROLOGY INDICATIONS
Source text for Eikon: ID:nBw8MPY1pa
Further company coverage: LCTX.A
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million